Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$182.18
-1.05-0.57%
À la fermeture: -
$182.18
0.000.00%
Après les heures de négociation: Oct 24, 4:00 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Quest Diagnostics Inc a un objectif de cours consensus de $182.3, basé sur les évaluations des 20 analystes. Le plus élevé est de $215 attribué par Jefferies le octobre 21, 2025, et le plus bas est de $140 attribué par Wells Fargo le février 3, 2023. Les 3 dernières évaluations d'analystes ont été publiées par Barclays, Truist Securities et Leerink Partners le octobre 22, 2025, octobre 22, 2025 et octobre 21, 2025. Avec un objectif de cours moyen de $203.33 entre Barclays, Truist Securities et Leerink Partners, il y a une variation implicite de 11.61% upside pour Quest Diagnostics Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Barclays
Truist Securities
Leerink Partners
Jefferies
UBS
1calculé à partir des notes des analystes
Notes d'analystes pour Quest Diagnostics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/22/2025 | 7.04% | Barclays | $190 → $195 | Maintains | Equal-Weight | |||
10/22/2025 | 12.53% | Truist Securities | $195 → $205 | Maintains | Hold | |||
10/21/2025 | 15.27% | Leerink Partners | $203 → $210 | Maintains | Outperform | |||
10/21/2025 | 18.02% | Jefferies | $200 → $215 | Maintains | Buy | |||
10/17/2025 | 4.29% | UBS | $180 → $190 | Maintains | Neutral | |||
10/17/2025 | 15.27% | Mizuho | $190 → $210 | Maintains | Outperform | |||
10/08/2025 | 4.29% | Evercore ISI Group | $185 → $190 | Maintains | In-Line | |||
10/02/2025 | 4.29% | Barclays | $185 → $190 | Maintains | Equal-Weight | |||
08/25/2025 | 6.49% | Baird | $194 → $194 | Downgrade | Outperform → Neutral | |||
07/23/2025 | -1.2% | UBS | $175 → $180 | Maintains | Neutral | |||
07/23/2025 | 5.39% | Truist Securities | $190 → $192 | Maintains | Hold | |||
07/23/2025 | -2.29% | Deutsche Bank | $160 → $178 | Maintains | Hold | |||
07/22/2025 | 9.78% | Jefferies | $195 → $200 | Maintains | Buy | |||
07/18/2025 | -3.94% | UBS | $176 → $175 | Maintains | Neutral | |||
05/06/2025 | 4.29% | JP Morgan | $180 → $190 | Maintains | Neutral | |||
04/28/2025 | 9.78% | Piper Sandler | $180 → $200 | Maintains | Neutral | |||
04/23/2025 | 4.29% | Truist Securities | $182 → $190 | Maintains | Hold | |||
04/23/2025 | 1.55% | Barclays | $175 → $185 | Maintains | Equal-Weight | |||
04/23/2025 | -1.2% | Evercore ISI Group | $175 → $180 | Maintains | In-Line | |||
04/23/2025 | 6.49% | Baird | $191 → $194 | Maintains | Outperform | |||
04/09/2025 | 3.74% | Mizuho | $178 → $189 | Maintains | Outperform | |||
04/02/2025 | 7.04% | Redburn Atlantic | → $195 | Initiates | → Buy | |||
03/20/2025 | 4.84% | Baird | $190 → $191 | Maintains | Outperform | |||
03/04/2025 | 1.55% | Citigroup | $185 → $185 | Downgrade | Buy → Neutral | |||
02/04/2025 | -1.2% | JP Morgan | $173 → $180 | Maintains | Neutral | |||
02/03/2025 | -2.29% | Mizuho | $177 → $178 | Maintains | Outperform | |||
02/03/2025 | -6.69% | UBS | $166 → $170 | Maintains | Neutral | |||
02/03/2025 | -1.2% | Piper Sandler | $165 → $180 | Reiterates | Neutral → Neutral | |||
01/31/2025 | -0.1% | Truist Securities | $172 → $182 | Maintains | Hold | |||
01/31/2025 | -3.94% | Barclays | $168 → $175 | Maintains | Equal-Weight | |||
01/06/2025 | -4.49% | Leerink Partners | $169 → $174 | Upgrade | Market Perform → Outperform | |||
12/23/2024 | -2.84% | Mizuho | $174 → $177 | Maintains | Outperform | |||
12/17/2024 | -5.59% | Morgan Stanley | $145 → $172 | Upgrade | Equal-Weight → Overweight | |||
12/13/2024 | -0.1% | B of A Securities | $179 → $182 | Maintains | Buy | |||
12/09/2024 | 1.55% | Jefferies | $175 → $185 | Assumes | Buy → Buy | |||
10/28/2024 | -9.43% | Piper Sandler | $150 → $165 | Maintains | Neutral | |||
10/24/2024 | -4.49% | Mizuho | $160 → $174 | Maintains | Outperform | |||
10/23/2024 | -5.59% | Truist Securities | $165 → $172 | Maintains | Hold | |||
10/23/2024 | -8.88% | UBS | $165 → $166 | Maintains | Neutral | |||
10/23/2024 | 1.55% | Citigroup | $165 → $185 | Maintains | Buy | |||
10/23/2024 | -7.78% | Barclays | $154 → $168 | Maintains | Equal-Weight | |||
10/23/2024 | -0.1% | Baird | $157 → $182 | Upgrade | Neutral → Outperform | |||
10/07/2024 | -9.43% | Truist Securities | $158 → $165 | Maintains | Hold | |||
08/28/2024 | -9.43% | Evercore ISI Group | → $165 | Reinstates | → In-Line | |||
08/27/2024 | -15.47% | Barclays | $144 → $154 | Maintains | Equal-Weight | |||
07/29/2024 | -17.66% | Piper Sandler | $145 → $150 | Maintains | Neutral | |||
07/24/2024 | -15.47% | Baird | $153 → $154 | Maintains | Neutral | |||
07/15/2024 | -13.27% | Truist Securities | $150 → $158 | Maintains | Hold | |||
07/10/2024 | -9.43% | Citigroup | $145 → $165 | Upgrade | Neutral → Buy | |||
07/05/2024 | -16.02% | Baird | $145 → $153 | Maintains | Neutral | |||
05/30/2024 | -14.92% | JP Morgan | $152 → $155 | Maintains | Neutral | |||
04/25/2024 | -20.96% | Barclays | $138 → $144 | Maintains | Equal-Weight | |||
04/24/2024 | -20.41% | Citigroup | $135 → $145 | Maintains | Neutral | |||
04/24/2024 | -19.86% | UBS | $139 → $146 | Maintains | Neutral | |||
04/24/2024 | -17.66% | Truist Securities | $145 → $150 | Maintains | Hold | |||
04/24/2024 | -14.92% | Mizuho | $150 → $155 | Maintains | Buy | |||
03/20/2024 | -20.41% | Truist Securities | → $145 | Reiterates | Hold → Hold | |||
02/26/2024 | -25.9% | Leerink Partners | → $135 | Initiates | → Market Perform | |||
02/07/2024 | -14.92% | Jefferies | $140 → $155 | Upgrade | Hold → Buy | |||
02/02/2024 | -20.41% | Truist Securities | $150 → $145 | Maintains | Hold | |||
12/20/2023 | -17.66% | Truist Securities | $145 → $150 | Maintains | Hold | |||
12/12/2023 | -12.17% | B of A Securities | $140 → $160 | Upgrade | Neutral → Buy | |||
12/11/2023 | -20.41% | Citigroup | $130 → $145 | Maintains | Neutral | |||
12/07/2023 | -24.8% | UBS | $135 → $137 | Maintains | Neutral | |||
11/17/2023 | -18.21% | JP Morgan | $148 → $149 | Maintains | Neutral | |||
11/06/2023 | -23.15% | Piper Sandler | $130 → $140 | Maintains | Neutral | |||
10/25/2023 | -28.64% | Citigroup | $142 → $130 | Maintains | Neutral | |||
10/16/2023 | -28.64% | Piper Sandler | $145 → $130 | Maintains | Neutral | |||
08/03/2023 | -20.41% | Morgan Stanley | $145 → $145 | Reiterates | Equal-Weight → Equal-Weight | |||
06/29/2023 | -20.41% | Piper Sandler | → $145 | Initiates | → Neutral | |||
05/10/2023 | -20.41% | Morgan Stanley | $158 → $145 | Maintains | Equal-Weight | |||
05/02/2023 | -18.76% | B of A Securities | $166 → $148 | Downgrade | Buy → Neutral | |||
04/03/2023 | -22.06% | Citigroup | $125 → $142 | Upgrade | Sell → Neutral | |||
03/17/2023 | -12.17% | Truist Securities | $170 → $160 | Maintains | Hold | |||
03/17/2023 | -9.43% | Mizuho | → $165 | Reiterates | → Buy | |||
02/03/2023 | -23.15% | Wells Fargo | $135 → $140 | Maintains | Equal-Weight | |||
01/25/2023 | -19.86% | Credit Suisse | $143 → $146 | Maintains | Neutral | |||
01/23/2023 | -12.72% | Evercore ISI Group | → $159 | Initiates | → In-Line | |||
01/12/2023 | -15.47% | Baird | $143 → $154 | Maintains | Neutral | |||
01/06/2023 | -13.27% | Morgan Stanley | $146 → $158 | Maintains | Equal-Weight | |||
12/14/2022 | -9.43% | Mizuho | $160 → $165 | Maintains | Buy | |||
11/17/2022 | -31.39% | Citigroup | $145 → $125 | Downgrade | Neutral → Sell |
FAQ
Quel est le cours indicatif de l'action Quest Diagnostics (DGX) ?
Le dernier objectif de prix pour Quest Diagnostics (NYSE:DGX) a été rapporté par Barclays le octobre 22, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $195.00 s'attendant à ce que DGX se rise dans les 12 prochains mois (un possible changement de 7.04% upside). 36 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Quest Diagnostics (DGX) ?
La dernière note d'analyste pour Quest Diagnostics (NYSE:DGX) a été fournie par Barclays, et Quest Diagnostics maintenu leur note equal-weight.
Quand a eu lieu la dernière mise à niveau pour Quest Diagnostics (DGX) ?
La dernière amélioration pour Quest Diagnostics Inc a eu lieu le janvier 6, 2025 lorsque Leerink Partners a augmenté leur objectif de prix à $174. Leerink Partners avait précédemment a market perform pour Quest Diagnostics Inc.
Quand a eu lieu la dernière dégradation pour Quest Diagnostics (DGX) ?
La dernière réduction pour Quest Diagnostics Inc a eu lieu le août 25, 2025 lorsque Baird a changé leur objectif de prix de $194 à $194 pour Quest Diagnostics Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Quest Diagnostics (DGX) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Quest Diagnostics, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Quest Diagnostics a été déposée le octobre 22, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 22, 2026.
La note d'analyste pour Quest Diagnostics (DGX) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Quest Diagnostics (DGX) était un maintenu avec un objectif de prix de $190.00 à $195.00. Le prix actuel de Quest Diagnostics (DGX) est de $182.18, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.